Updates in Advanced Urothelial Carcinoma - Highlights from ASCO 2018 - Petros Grivas

June 21, 2018

(Length of Discussion: 23 min)

Petros Grivas and Alicia Morgans talk post-ASCO 2018 about a number of studies and abstracts presented. The first they review is the ABACUS study presented by Thomas Powles, MD. This single arm, phase II study investigated two cycles of atezolizumab (1200mg every three weeks) prior to radical cystectomy among patients with T2-4N0M0 urothelial carcinoma. 

The second study they discuss is a 2-Year Follow-Up from the KEYNOTE-045 Trial.  KEYNOTE-045, 542 patients with advanced urothelial cancer that recurred or progressed after platinum-based chemotherapy were randomly assigned to receive pembrolizumab (n=270; 200 mg every 3 weeks) or the investigator's choice of chemotherapy (n=272) with paclitaxel (175 mg/m2 every 3 weeks), docetaxel (75 mg/m2 every 3 weeks), or vinflunine (320 mg/m2 every 3 weeks). In closing, they review abstract 4504 in the non-checkpoint inhibitor space.

Petros Grivas MD, Ph.D. a medical oncologist at Seattle Cancer Care Alliance with expertise in genitourinary cancers such as bladder cancer, prostate cancer and testis cancer.  He is the Clinical Director, of the Genitourinary Cancers Program at the University of Washington Medicine and an Associate Professor of the Department of Medicine, Division of Oncology at the University of Washington School of Medicine.

Alicia Morgans, MD, MPH

Presentations Discussed in the Conversations:
Pembrolizumab versus Investigator’s Choice (Paclitaxel, Docetaxel, or Vinflunine) in Recurrent, Advanced Urothelial Cancer: 2-Year Follow-Up from KEYNOTE-045 Trial

A phase II Study Investigating the Safety and Efficacy of Neoadjuvant Atezolizumab in Muscle Invasive Bladder Cancer (ABACUS)

Abstract 4504: Updated Results from the Enfortumab Vedotin Phase 1 (EV-101) Study in Patients with Metastatic Urothelial Cancer